SHANGHAI, Oct. 29, 2021 /PRNewswire/ -- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet
technology company offering healthcare professionals the online
healthcare information, professional training and educational
services platform and patients the patient management platform,
today announced its self-developed patient management system
improves Duration of Therapy ("DOT") by 40.4% for liver cancer
patients, which contributes to the maximum efficiency of drugs,
successful treatment and longer patient survival terms.
By utilizing its self-developed patient management system,
Zhongchao provides patients with coherent treatment process
management through education, phone call follow-up, utility of
intelligent tools to assist patients to control possible adverse
reactions during treatment, psychological counseling, drugs usages
reminder, treatment-related questions answering, and patients
supervision to ensure that patients follow instructions as
prescribed. For nearly 20,000 liver cancer patient users of the
Company's patient management system, 180,000 medication usage
records showed that compared to the DOT in clinical study, the DOT
of the users improved 40.4% as a result of the improved treatment
adherence. Meanwhile, according to the research article published
by BMJ, good adherence was associated with lower mortality, and the
mortality risks could reduce by 44% for patients with good
adherence.
According to The Global Cancer Observatory, there were around
400,000 new liver cancer cases in 2020 in China. Currently, the treatment of liver
cancer mainly relies on surgical resection, interventional therapy,
radiotherapy and liver transplantation while all treatment methods
have certain limitations, however, combining with systemic
therapies such as targeted drugs can improve the treatments effect.
However, during the systemic therapies, one or several adverse
reactions often lower patients' life quality and hinder their
mental health, increasing difficulties in treatment and causing
negative impact on patients' survival terms. As such, during the
treatment, Zhongchao, through its patient management system,
closely monitors and deals with the adverse reactions and focuses
on managing follow-up visits to improve patients physical and
mental conditions. The Company will continue to invest in its
patient management system, aiming to benefit all cancer
patients.
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is
a platform-based internet technology company. It
provides online healthcare information, professional training and
educational services to healthcare professionals under its "MDMOOC"
platform (www.mdmooc.org) and to the public under its "Sunshine
Health Forums" platform (www.ygjkclass.com) in China. Through its subsidiaries, the Company
also operates a platform offering patient management services. More
information about the Company can be found at its investor
relations website at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the
Company's future business development; product and service demand
and acceptance; changes in technology; economic conditions; the
growth of the professional training and educational services market
in China and the other
international markets the Company plans to serve; reputation and
brand; the impact of competition and pricing; government
regulations; fluctuations in general economic and business
conditions in China and the
international markets the Company plans to serve and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the SEC, the length
and severity of the recent coronavirus outbreak, including its
impacts across our business and operations. For these
reasons, among others, investors are cautioned not to place undue
reliance upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings with the
SEC, which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these forward–looking
statements to reflect events or circumstances that arise after the
date hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:https://www.prnewswire.com/news-releases/zhongchao-inc-announces-its-patient-management-system-improves-its-liver-cancer-patients-duration-of-therapy-by-40-promoting-successful-treatment-301411680.html
SOURCE Zhongchao Inc.